

Emollient + Plus



ISSUE - 4




Role of Actives in Emollients in Atopic Dermatitis

B. S. Chandrashekar¹ | Thomas Luger² | S. C. Rajendran³ | Anchala Parathasaradhi⁴ Jayakar Thomas⁵ | Anil Ganjoo⁶ | Divya Sharma⁷ | Rajetha Damishetty⁸ | Nazima Ruby⁸ Vijayalakshmi Sujay¹⁰ | Snehal Sriram¹¹ | Satish Udare¹² | Dhara Shah¹³ | Jayesh Rajgopal¹⁴



Emollient Plus contains active, non-medicated substances which can improve AD lesions through several synergistic modes of action, including preserving barrier lipid. Use of Emollient Plus significantly improves clinical signs and symptoms, increases skin hydration, and improves the quality of life of subjects with mild AD



Investigational Product	Emollient Plus
Reference Product	1% pimecrolimus cream
Study Objective	Evaluate the time to flare, defined as the time to the next disease exacerbation
Study Design	Open-label, single-arm, interventional, multicentre study
No. of Subjects	101 patients (both genders, aged >12 years)
Indication	Mild atopic dermatitis
Study Duration	4 Months

Result:

- Emollient plus significantly reduced pruritis and improved skin hydration in patients with AD.
- Pimecrolimus followed by **Emollient plus** is a **useful treatment approach in the management of mild to moderate AD.**
- Emollient plus after 1% pimecrolimus, was able to maintain regression of flare-up to at least 4 months in 99% of the patients.

